pharmacodynamics | CMAC

pharmacodynamics

New Drug Formulations of Posaconazole: Brief Clinical Pharmacology Review

Posaconazole is a second generation triazole with a broad spectrum of activity, which first appeared on the market in 2005 in the form of a suspension for oral administration. Despite some progress made in the framework of clinical trials, the …

A Novel View on Common Antibiotics: How to Properly Use Pharmacodynamic Parameters

The efficacy of antibacterial therapy is determined by multiple factors, including pharmacokinetic (PK) parameters of the antimicrobial agent. The predictive value of PK parameters has been confirmed in a number of in vivo experiments and clinical …

Anti-Staphylococcal Effects of Telavancin and Vancomycin in In Vitro Simulations of the Antibiotic Pharmacokinetics

Telavancin (TLV) is an investigational lipoglycopeptide with multiple mechanism of action. It exhibits rapid bactericidal activity against gram-positive bacteria, including methicillin-susceptible and -resistant, glycopeptide-intermediate and …

Comparative Pharmacodynamics of Daptomycin and Vancomycin with Staphylococcus aureus in an in vitro Dynamic Model

To compare the pharmacodynamics of daptomycin (DAP) and vancomycin (VAN) as well as killing kinetics of S. aureus with different MICs were studied at widely ranged AUC/MIC ratios. Two clinical isolates, S. aureus 866 (MICDAP 0.35 µ/ml and MICVAN 0.70 …